Unresectable Locally Advanced or Metastatic Solid Tumors Study

Phase: 2

Status: Ongoing

About

A Phase 2 Study of Ladiratuzumab Vedotin in Advanced Solid Tumors


Details

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors (Cohorts for Prostate Cancer and Melanoma open)

Sponsor: Seagen Inc

NCT04032704

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top